Skip to content
Homepage
Author:
Vera Therapeutics
Posted Date:
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics
July 11, 2026
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics
July 11, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics
July 7, 2026
